ArticleScientific reports2017
Pharmacological use of a novel scaffold, anomeric N,N-diarylamino tetrahydropyran: molecular similarity search, chemocentric target profiling, and experimental evidence.
Article in Scientific reports, 2017. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 10 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
10 citing papers in PubMed.
- Discovery of Anti-Neuroinflammatory Compounds in Alzheimer's Disease: Current Trends and Future Perspectives.Molecular neurobiology · 2026Review
- NO classifier prediction of anti neuroinflammatory agents using text mining of 3D molecular fingerprints.Scientific reports · 2024Article
- Prediction of chemical warfare agents based on cholinergic array type meta-predictors.Scientific reports · 2022Article
- Random-forest model for drug-target interaction prediction via Kullbeck-Leibler divergence.Journal of cheminformatics · 2022Article
- MAP/Microtubule Affinity Regulating Kinase 4 Inhibitory Potential of Irisin: A New Therapeutic Strategy to Combat Cancer and Alzheimer's Disease.International journal of molecular sciences · 2021Article
- Positioning of an unprecedented spiro[5.5]undeca ring system into kinase inhibitor space.Scientific reports · 2020Article
- Repurposing of FDA approved ring systems through bi-directional target-ring system dual screening.Scientific reports · 2020Article
- Progress and Prospects of Polymer-Based Drug Delivery Systems for Bone Tissue Regeneration.Polymers · 2020Review
- Comparing a Query Compound with Drug Target Classes Using 3D-Chemical Similarity.International journal of molecular sciences · 2020Article
- Discovery of CNS-Like D3R-Selective Antagonists Using 3D Pharmacophore Guided Virtual Screening.Molecules (Basel, Switzerland) · 2018Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
11 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Rational drug design against a determined target (disease, pathway, or protein) is the main strategy in drug discovery. However, regardless of the main strategy, chemists really wonder how to maximize the utility of their new compounds by drug repositioning them as clinical drug candidates in drug discovery. In this study, we started our drug discovery "from curiosity in the chemical structure of a drug scaffold itself" rather than "for a specific target". As a new drug scaffold, anomeric diarylamino cyclic aminal scaffold 1, was designed by combining two known drug scaffolds (diphenylamine and the most popular cyclic ether, tetrahydropyran/tetrahydrofuran) and synthesized through conventional Brønsted acid catalysis and metal-free α-C(sp
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.